This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2001;286:2660.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has approved tenofovir disoproxil fumarate tablets (Viread, Gilead Sciences Inc, Foster City, Calif) in combination with other antiretroviral agents for the treatment of HIV-1 infection. Viread is a prodrug of tenofovir (nucleotide analog), which exhibits activity against HIV reverse transcriptase.

The indication is based on analyses of plasma HIV-1 RNA levels and CD4 cell counts in a controlled study of 24 weeks' duration and in a controlled, dose-ranging study of 48 weeks' duration. Treatment-experienced adults with evidence of HIV-1 viral replication despite ongoing antiretroviral therapy were randomized to receive either Viread or placebo in addition to their stable background regimen of antiretroviral agents. In both studies, the mean baseline CD4 cell count was approximately 410/µL, median baseline plasma HIV RNA was approximately 3500 copies/mL, and mean duration of prior HIV treatment was approximately 5 years.

In both studies, statistically significant differences of 0.5-0.6 log₁₀ decline in plasma HIV . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Adverse Renal and Metabolic Effects Associated with Oral Sodium Phosphate Bowel Preparation
Heher et al.
CJASN 2008;3:1494-1503.
ABSTRACT | FULL TEXT